

SPRING GROUP MEETING

Seattle

Cancer Care Delivery (CCD) Committee

APRIL 3-6, 2024 | SEATTLE, WASHINGTON

Cancer Control & Prevention Committees

Leadership

Vice-Chair NCORP: Dawn L. Hershman, MD, MS
 Cancer Care Delivery Co-Chairs: Dawn L. Hershman, MD, MS
 Scott D. Ramsey, MD, PhD
 Cancer Survivorship Co-Chairs: Halle C.F. Moore, MD
 Melinda L. Irwin, PhD, MPH
 Palliative & End of Life Co-Chairs: Robert S. Krouse, MD, FACS
 Marie Bakitas, DNSc, CRNP
 Prevention and Epidemiology Co-Chairs: Banu Arun, MD
 Marian L. Neuhouser, PhD, RD
 Symptom Control & QOL Co-Chairs: Michael J. Fisch, MD, MPH
 Norah Lynn Henry, MD, PhD
 Executive Officers: Katherine D. Crew, MD (CCD, Prevention,
 Symptom Control)
 Virginia Sun, PhD, MSN, RN (Palliative, Survivorship)
 Senior Advisor: Frank L. Meyskens, Jr., MD
 Statisticians: Katherine Guthrie, PhD
 Cathy Tangen, DrPH
 Joseph M. Unger, PhD
 Kathryn B. Arnold, MS
 Amy K. Darke, MS
 Danika Lew, MA
 Sarah Colby, MS
 Administrative Lead SDMC: Monica Yee, CCRP

Scientific Leadership

NCORP Representative: Scott Edward Delacrois, Jr., MD
 Helen Heng-Shan Moon, MD
 Radiation Oncology: Eileen P. Connolly, MD, PhD (CCD, Prevention)
 Kiri A. Cook, MD (Survivorship, Symptom Control)
 Erin F. Gillespie, MD (Symptom Control)
 Surgery Committee: Robert S. Krouse, MD, FACS
 Translational Medicine: James Rae, PhD
 Liaisons:
 Barlogie-Salmon Myeloma Committee: Charles S. Kuzma, MD
 Breast Committee: Mariya Rozenblit, MD (Survivorship)
 Helen K. Chew, MD (Symptom Control)
 Dawn Hershman, MD, MS (CCD)
 Banu Arun, MD (Prevention)
 Philip Lammers, MD
 Early Therapeutics & Rare Cancers: Lara E. Davis, MD (Survivorship)
 Jason M. Prosek, MD
 Gastrointestinal Committee: Jason A. Zell, DO (Prevention)
 Afsaneh Barzi, MD (CCD)
 Genitourinary Committee: Clara Hwang, MD
 Sarah P. Psutka, MD

International Liaison: Kathy S. Albain, MD
 Leukemia Committee: Stephanie B. Tsai, MD
 Lung Committee: Gary E. Goodman, MD
 Lymphoma Committee: Hayder Saeed, MD
 Melanoma Committee: Sancy Leachman, MD, PhD
 Thach-Giao Truong, MD (Survivorship)
 Recruitment & Retention: Allison M. Caban-Holt, PhD
 Digital Engagement: Jennifer R. Klemp, PhD (Survivorship)
 Krishna Soujanya Gunturu, MD (Survivorship)
 Mina S. Sedrak, MD (CCD)
 Katherine D. Crew, MD (Prevention)
 Michael J. Fisch, MD (Symptom Control)
 Veterans Affairs: Yeun-Hee Anna Park, MD (Symptom Control)
 Neha Patel, MD (Survivorship)
 Jacqueline Ann Gesek, BSN, RN (Nursing)

Designates

Oncology Research Professionals:

CRAs: Amanda R. Dinsdale, MHA, CCRC
 Amy Jo Koffarnus, BS, CCRP
 Samantha Wright, MS, CCRP
 Shirley S. Sui, BS
 Nurses: Connie Szczepanek, RN, BSN
 Melyssa W. Foust, MSN, RN
 Pharmaceutical Sciences Committee: Kimberly McConnell, PharmD
 Siu-Fun Wong, PharmD
 Sun "Coco" Yang, PharmD, PhD
 SDMC Data Coordinators: Kimberly Carvalho, BA
 Sam Dzingle, BA
 Matthew Eng, PharmD
 Diane Liggett, BS, CCRP
 Roxanne Topacio, CCRP
 Monica Yee, BA, CCRP
 Recruitment & Retention Specialist: Jamie Sundstrom, BS
 Patient Advocates: Barbara Segarra-Vazquez, DHSc (CCD)
 Amy Geschwender, PhD (Symptom Control)
 Hartley "Lee" M. Jones, MBA (Survivorship)
 Cheryl L. Jernigan, CPA (Prevention)
 Valerie Fraser (Palliative)
 Sr. Protocol Project Manager (CCD and Prevention): Patricia O'Kane
 Protocol Project Manager (Survivorship): Megan Keim
 Protocol Project Manager (Symptom Control): Justine Trevino
 Protocol Project Manager (Palliative Care): Andrea Garcia
 Clinical Trials Program Manager (Palliative Care): Laura Gildner, MS
 Clinical Trials Program Manager (CCD; Prevention;
 Survivorship; Symptom Control): Mariah Norman, MS

Cancer Care Delivery (CCD) Committee

Leadership

Co-Chairs: Dawn L. Hershman, MD, MS
 Scott D. Ramsey, MD, PhD
 Veena Shankaran, MD, MS

Time/Location

Thursday, April 4, 2024 8:00 a.m. - 10:00 a.m.
 Room: Elwha AB (Level 5)

Agenda

Presentations:

Digital Strategies to Promote Physical Activity During Cancer Treatment:

A Pragmatic Hybrid Implementation-effectiveness Trial, Erin Gillespie, MD, University of Washington, Fred Hutchinson Cancer Center

A Prospective, Longitudinal Study of Employment and Related

Outcomes in Newly Diagnosed Patients with Metastatic Breast Cancer, Claire Sathe, MD, Columbia University Irving Medical Center

The University of New Mexico CREDIT Trial Experience, Bernard Tawfik,

MD, University of New Mexico Comprehensive Cancer Center

Committee Strategic Planning: Drs. Scott Ramsey, Dawn Hershman, Veena Shankaran

Active Studies

S1912CD, "A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery of a Proactive Financial Navigation Intervention (CREDIT)." Dr. V. Shankaran. Activated 7/26/21.

S2108CD, "Randomized Comparison of an Educationally Enhanced Genomic Tumor Board (eGTB) Intervention to Usual Practice of Incorporating Genomic Test Results into Clinical Care." Drs. J. Rueter, M. Trivedi, B Symington, P. Tseng, D. Hershman, S. Ramsey. Activated 8/22/22.

Active studies with CCD/CCP Components

S1703, "Randomized Non-inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) versus Usual Care in Patients with Metastatic Hormone Receptor Positive HER-2 Breast Cancer," Dr. M. Accordino. Activated 7/16/18.

S1904, "Cluster Randomized Controlled Trial of Patient and Provider Decision Support to Increase Chemoprevention Informed Choice Among Women with Atypical Hyperplasia or Lobular Carcinoma In

Situ – Making Informed Choices on Incorporating Chemoprevention into Care (MiCHOICE)." Dr. K. Crew. Activated: 9/1/20. (Committee: Prevention/Epidemiology)

Developing Studies/Miscellaneous Updates

S2309CD, Preventing Financial Adversity Among Early-stage Cancer Patients through Unrestricted Cash (PAYMENT) – Dr. V. Shankaran.
 • Resubmitted U34 in October 2023

S2417CD, A Pragmatic Randomized Controlled Trial to Evaluate the Effectiveness of an Intervention to Promote Guideline-Concordant Colorectal Cancer Surveillance – Dr. C. Veenstra.
 • Submitted R01 in October 2023

S2424CD, Lay Health Worker-led Intervention to Promote Goals of Care Communication – Drs. M. Patel, R. Parikh, and C. Manz.
 • Submitted R01 in February 2024

Patient-centered Video Education Intervention to Improve Rural Cancer Care Delivery – Drs. R. Holcombe and I. Okado.

Closed Studies

S1415CD, "A Pragmatic Trial To Evaluate a Guideline-Based Colony Stimulating Factor Standing Order Intervention and to Determine the Effectiveness of Colony Stimulating Factor Use as Prophylaxis for Patients Receiving Chemotherapy with Intermediate Risk for Febrile Neutropenia - Trial Assessing CSF Prescribing, Effectiveness and Risk (TrACER)." Drs. S. Ramsey, D. Hershman, G. Lyman, et al. Activated: 10/7/16. Closed: 4/15/20.

S1417CD, "Implementation of a Prospective Financial Impact Assessment Tool in Patients with Metastatic Colorectal Cancer." Dr. V. Shankaran. Activated: 4/15/16. Closed: 2/1/19.

Substudies (Economic Analyses / Cost Effectiveness from NCTN trials)

S1806, Healthcare Cost Comparison of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle-invasive Bladder Cancer, Drs. R. Vaidya and J. Unger.

Published Studies

Sex Differences in Adverse Event Reporting in SWOG Chemotherapy, Biologic/Immunotherapy and Targeted Agent Cancer Clinical Trials. Dr. J. Unger.

Cancer Care Delivery Committee

Trends in Obesity Prevalence Among Patients Enrolled in Clinical Trials for Obesity-related Cancers, 1986 to 2016. Dr. R. Vaidya.

Universal Viral Screening of Newly Diagnosed Cancer Patients in the United States: A Cost Efficiency Evaluation, Dr. R. Vaidya.

Publications

The publications listed below were received by the Group Chair's Office as published (including online), accepted, or submitted since the SWOG Fall 2023 Group Meeting. Conference abstracts are not included.

Because of journal embargo policies, journal names are omitted for submitted or accepted manuscripts.

Published/Accepted Manuscripts

S1204 Universal Viral Screening of Newly Diagnosed Cancer Patients in the United States: A Cost Efficiency Evaluation. Vaidya R, Unger J, Loomba R, Hwang J, Chugh R, Tincopa M, Arnold K, Hershman D, Ramsey S. *Cancer Research Communications* 3(9):1959-1965, 2023. <https://pubmed.ncbi.nlm.nih.gov/37707388/>

S1415CD Impact of Treatment Experience on Patient Knowledge of Colony Stimulating Factors Among Patients Receiving Cancer Chemotherapy: Evidence from S1415CD, A Large Pragmatic Trial. Lyman G, Bansal A, Sullivan S, Arnold K, Barlow W, Hershman D, Lad T, Ramsey S. *Supportive Care in Cancer* 598 Sep 28;31(10):598, 2023. <https://pubmed.ncbi.nlm.nih.gov/37770704/>

S1415CD Intervention non-adherence in The TrACER (S1415CD) study, a pragmatic randomized trial of a standardized order entry for colony stimulating factor prescribing. Hershman DL, Bansal A, Barlow W, Arnold K, Watabayashi K, Bell-Brown A, Sullivan S, Lyman G, Ramsey S. *JCO Oncology Practice* Dec;19(12):1160-1167, 2023. <https://pubmed.ncbi.nlm.nih.gov/37788414/>

Multiple Studies Association of Baseline Measures of Socioeconomic Deprivation and Healthcare Utilization in Patients Enrolled in SWOG Cancer Clinical Trials. Hershman D, Vaidya R, Till C, Barlow W, LeBlanc M, Ramsey S, Unger J. Accepted 2024.

None Sponsors' Perspectives on the Impact of the COVID-19 Public Health Emergency on Interventional Cancer Clinical Trial Protocols and Data Quality. Unger J, Stires H, Levit L, Stewart M, McKelvey B, Canin B, Connelly N, Dressler E, Flaherty K, Fredette P, Jones L, McCann P, Miller T, Ontilio A, Palmieri F, Patel T, Paul R, Smith G, Bruinooge S, Garrett-Mayer E, Lei X, Alva A, Schenkel C. *JCO Oncol Pract* Oct;19(10):907-916, 2023. <https://pubmed.ncbi.nlm.nih.gov/37643386/>

Submitted Manuscripts

Multiple Studies* Neighborhood Socioeconomic Deprivation and Patient-Reported Outcomes in Symptom Management Trials for Breast Cancer Patients. Vaidya R, Till C, Henry NL, Fisch M, Hershman D, Unger J. Submitted 2023. [*S0927,S1200,S1202]

Cancer Care Delivery (CCD) Committee

Accrual from trials that are open as of 12/31/2023 or have closed in the prior 18 Months by Institution and Study

	S1703	S1912CD	S2108CD	A191901	A231601C	A231901C	ACCL16N1	EAQ171CD	NHLBIMDS	NRGCC007
Ascension Providence Hospitals - Southfield	-	-	-	4	-	-	-	-	1	-
Banner University Medical Center - Tucson	1	-	-	-	-	-	-	-	-	-
Baptist Mem Health Care/Mid South Minority Underserved NCORP	-	-	-	-	-	1	-	5	3	-
Bay Area Tumor Institute NCORP	-	2	-	-	-	-	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	24	-	-	-	-	-	-	-	5	-
Cancer Research Consortium of West Michigan NCORP	-	5	-	-	-	1	3	-	-	-
Cancer Research for the Ozarks NCORP	-	10	25	-	-	-	-	-	-	-
Cancer Research of Wisconsin and Northern Michigan Consortium	11	5	29	1	-	-	-	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	8	1	96	-	-	-	-	-	1	-
Columbia University Minority Underserved NCORP	25	8	-	-	-	-	-	-	22	-
Columbus NCI Community Oncology Research Program	5	-	-	-	-	-	-	-	-	-
CommonSpirit Health Research Institute	10	-	31	-	-	-	-	-	-	-
Cotton O'Neil Cancer Center / Stormont Vail Health	1	-	-	-	-	-	-	-	-	-
Dayton NCI Community Oncology Research Program	3	1	-	-	-	-	-	-	-	-
Essentia Health NCI Community Oncology Research Program	-	-	109	-	-	-	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	-	-	-	-	-	-	-	-	22	-
Georgia Cares Minority Underserved NCORP	-	2	-	-	-	-	-	-	-	-
Georgia NCI Community Oncology Research Program	2	-	29	-	-	-	17	-	-	-
Gulf South Minority Underserved NCORP	6	2	-	-	2	-	-	-	-	-
Hawaii Minority Underserved NCORP	9	3	71	-	-	-	-	-	5	-
Heartland Cancer Research NCORP	18	7	117	-	-	-	-	-	-	1
Kaiser Permanente NCI Community Oncology Research Program	4	10	-	-	-	-	34	-	8	-
Kansas City Veterans Affairs Medical Center	-	-	-	-	-	-	-	-	4	-
Kansas Institute of Medicine Cancer and Blood Center	-	-	-	-	-	-	-	-	2	-
Lahey Hospital and Medical Center	4	-	-	-	-	-	-	-	-	-
Loyola University Medical Center	2	-	-	5	-	-	-	-	-	-
Mass Veterans Epidemiology Research and Information Center	-	-	-	-	-	-	-	-	36	-
Medical University of South Carolina Minority Underserved NCORP	-	-	-	-	-	-	-	-	5	-
Michigan Cancer Research Consortium NCORP	11	15	44	-	-	-	-	-	-	-

Cancer Care Delivery (CCD) Committee

Accrual from trials that are open as of 12/31/2023 or have closed in the prior 18 Months by Institution and Study

	S1703	S1912CD	S2108CD	A191901	A231601C	A231901C	ACCL16N1	EAQ171CD	NHLBIMDS	NRGCC07
Moffitt Cancer Center	-	-	-	-	-	-	-	-	8	-
Montana Cancer Consortium NCORP	9	1	51	-	-	-	-	-	-	-
Mount Sinai Hospital	3	-	-	-	-	-	-	-	-	-
MultiCare Tacoma General Hospital	-	-	-	22	-	-	-	1	-	-
NCORP of the Carolinas (Prisma Health NCORP)	6	1	-	-	-	-	-	-	2	-
Nevada Cancer Research Foundation NCORP	2	2	-	1	-	-	-	-	-	-
New Mexico Minority Underserved NCORP	15	11	-	-	-	-	-	-	-	-
Northwell Health NCORP	-	3	-	-	-	-	-	-	18	-
Oregon Health and Science University	-	-	-	-	-	-	-	-	11	-
Pacific Cancer Research Consortium NCORP	10	13	-	-	-	-	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	5	16	9	-	-	-	-	-	-	-
UC Davis Comprehensive Cancer Center LAPS	1	-	-	3	-	-	-	-	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	-	-	-	-	-	-	-	23	-
UC San Diego Moores Cancer Center	-	-	-	-	-	-	-	-	32	-
University of Arkansas for Medical Sciences	4	-	-	-	-	-	-	-	-	-
University of Colorado Cancer Center LAPS	-	-	-	-	-	-	-	-	13	-
University of Kansas Cancer Center - MCA Rural MU NCORP	7	4	62	-	-	-	-	-	-	22
University of Rochester LAPS	4	-	-	-	-	-	-	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	-	-	-	2	-	-	-	-	-	-
Upstate Carolina Consortium Comm Oncology Research Program	-	5	35	-	-	-	-	-	-	-
Western States Cancer Research NCORP	-	1	-	1	-	-	-	-	-	-
William Beaumont Hospital-Royal Oak	-	-	-	-	-	-	-	-	2	-
Wisconsin NCI Community Oncology Research Program	3	4	-	-	-	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	39	-	-	-	-	-	-	-	7	-
ALLIANCE	14	9	40	-	-	-	-	-	-	-
ECOG-ACRIN	26	20	24	-	-	-	-	-	-	-
NRG	18	8	-	-	-	-	-	-	-	-
Total	310	169	772	39	2	2	54	6	230	23

